JAZZ News and Press, Jazz Pharmaceuticals plc From 05/01/24

Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference PR Newswire DUBLIN , May 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the BofA Securities 2024 Gl...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

2024-04-30 17:20:33 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals: Cheap But Complicated Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript Avadel surges afte...

2024-04-30 16:00:00 ET Summary Harmony Biosciences Holdings, Inc. stock price fell sharply in October last year, as the lead drug pitolisant - approved to treat narcolepsy - missed endpoints in a late stage IH study. The company's Q3 2023 earnings saw Wakix revenues up 37% YoY and...

NORTHAMPTON, MA / ACCESSWIRE / April 30, 2024 / Jazz Pharmaceuticals: At Jazz, Earth Month provides an opportunity to reflect on steps we can take to become more conscious of our actions to positively impact the planet. For more information on our approach to sustainable practices, read our Co...

Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 PR Newswire Overall survival and additional long-term follow-up data from the Phase 2b HERIZON-BTC-01 trial in previously treated HER2-positive metastatic biliary tract cancer ...

Originally published by Jazz Pharmaceuticals NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Purple Day spotlights epilepsy and the challenges that people face when living with the condition. Jazz wants the epilepsy community know that they are not alone and showed support by sporting pu...

2024-04-18 13:26:38 ET Summary Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav, which has replaced Xyrem as the top treatment for narcolepsy. The company's narcolepsy franchise is facing competition from Avadel Pharmaceuticals' Lumryz, but Jazz is defend...

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN , April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednes...

2024-04-17 07:04:07 ET More on Eli Lilly Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets GLP-1s ...